Works matching AU Kim, Kihyun

Results: 300
    1
    2
    3
    4
    5
    6
    7

    A Formal Framework for Patch Management.

    Published in:
    International Journal of Interdisciplinary Telecommunications & Networking, 2013, v. 5, n. 2, p. 18, doi. 10.4018/jitn.2013040102
    By:
    • Francia, Guillermo A.;
    • Kihyun Kim;
    • Byungoh Ahn;
    • Sen Xin Zhou
    Publication type:
    Article
    8
    9
    10
    11
    12
    13
    14
    15
    16
    17
    18
    19
    20
    21
    22
    23
    24
    25
    26
    27

    Intestinal Lymphoma: Exploration of the Prognostic Factors and the Optimal Treatment.

    Published in:
    Leukemia & Lymphoma, 2004, v. 45, n. 2, p. 339, doi. 10.1080/10428190310001593111
    By:
    • Jeeyun Lee, Michele;
    • Won Seog Kiw, Michele;
    • Kihyun Kim, Michele;
    • Young Hyeh Ko;
    • Jae Jun Kim, Michele;
    • Young Ho Kim;
    • Ho Kyung Chun, Michele;
    • Woo Yong Lee;
    • Joon Oh Park, Michele;
    • Chul Won Jung, Michele;
    • Young-Hyuck Im, Michele;
    • Mark H. Lee, Michele;
    • Won Ki Kang, Michele;
    • Keunchil Park
    Publication type:
    Article
    28
    29
    30

    Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy.

    Published in:
    British Journal of Haematology, 2021, v. 194, n. 4, p. 784, doi. 10.1111/bjh.17541
    By:
    • Quach, Hang;
    • Nooka, Ajay;
    • Samoylova, Olga;
    • Venner, Christopher P.;
    • Kim, Kihyun;
    • Facon, Thierry;
    • Spencer, Andrew;
    • Usmani, Saad Z.;
    • Grosicki, Sebastian;
    • Suzuki, Kenshi;
    • Delimpasi, Sosana;
    • Weisel, Katja;
    • Obreja, Mihaela;
    • Zahlten‐Kumeli, Anita;
    • Mateos, Maria‐Victoria
    Publication type:
    Article
    31
    32

    Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS Study.

    Published in:
    Annals of Hematology, 2025, v. 104, n. 1, p. 515, doi. 10.1007/s00277-024-05958-8
    By:
    • Fu, Weijun;
    • Bang, Soo-Mee;
    • Huang, Honghui;
    • Kim, Kihyun;
    • Li, Wei;
    • An, Gang;
    • Lee, Je-Jung;
    • Cai, Zhen;
    • Jin, Jie;
    • Wang, Yafei;
    • Chim, Chor Sang;
    • Carson, Robin;
    • Liu, Rui;
    • Zhao, Man;
    • Chen, Xi;
    • Cui, Canchan;
    • Hou, Jian;
    • Wang, Jianxiang
    Publication type:
    Article
    33

    Correction to: Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS study.

    Published in:
    2024
    By:
    • Fu, Weijun;
    • Bang, Soo-Mee;
    • Huang, Honghui;
    • Kim, Kihyun;
    • Li, Wei;
    • An, Gang;
    • Lee, Je-Jung;
    • Cai, Zhen;
    • Jin, Jie;
    • Wang, Yafei;
    • Chim, Chor Sang;
    • Carson, Robin;
    • Liu, Rui;
    • Zhao, Man;
    • Chen, Xi;
    • Cui, Canchan;
    • Hou, Jian;
    • Wang, Jianxiang
    Publication type:
    Correction Notice
    34
    35

    Busulfan plus melphalan versus high-dose melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma with high-risk features (KMM 2015).

    Published in:
    Annals of Hematology, 2023, v. 102, n. 8, p. 2233, doi. 10.1007/s00277-023-05308-0
    By:
    • Kim, Mihee;
    • Lee, Je-Jung;
    • Min, Chang-Ki;
    • Lee, Ji Yun;
    • Jo, Jae-Cheol;
    • Yoon, Sung-Soo;
    • Lim, Sung-Nam;
    • Do, Young Rok;
    • Kim, Kihyun;
    • Lee, Jae Hoon;
    • Yoo, Kwai Han;
    • Bae, Sung Hwa;
    • Yi, Jun Ho;
    • Jung, Jongheon;
    • Eom, Hyeon-Seok;
    • Jung, Sung-Hoon
    Publication type:
    Article
    36

    Daratumumab plus bortezomib, cyclophosphamide, and dexamethasone in Asian patients with newly diagnosed AL amyloidosis: subgroup analysis of ANDROMEDA.

    Published in:
    Annals of Hematology, 2023, v. 102, n. 4, p. 863, doi. 10.1007/s00277-023-05090-z
    By:
    • Suzuki, Kenshi;
    • Wechalekar, Ashutosh D.;
    • Kim, Kihyun;
    • Shimazaki, Chihiro;
    • Kim, Jin Seok;
    • Ikezoe, Takayuki;
    • Min, Chang-Ki;
    • Zhou, Fude;
    • Cai, Zhen;
    • Chen, Xiaonong;
    • Iida, Shinsuke;
    • Katoh, Nagaaki;
    • Fujisaki, Tomoaki;
    • Shin, Ho-Jin;
    • Tran, NamPhuong;
    • Qin, Xiang;
    • Vasey, Sandra Y.;
    • Tromp, Brenda;
    • Weiss, Brendan M.;
    • Comenzo, Raymond L.
    Publication type:
    Article
    37
    38
    39
    40
    41
    42
    43
    44
    45

    Variation in immunoglobulin use and impact on survival in myeloma.

    Published in:
    EJHaem, 2024, v. 5, n. 4, p. 690, doi. 10.1002/jha2.938
    By:
    • Chai, Khai Li;
    • Wellard, Cameron;
    • Thao, LTP;
    • Aoki, Naomi;
    • Moore, Elizabeth M;
    • Augustson, Bradley M;
    • Bapat, Akshay;
    • Blacklock, Hilary;
    • Chng, Wee J;
    • Cooke, Rachel;
    • Forsyth, Cecily J;
    • Goh, Yeow‐Tee;
    • Hamad, Nada;
    • Harrison, Simon J;
    • Ho, P Joy;
    • Hocking, Jay;
    • Kerridge, Ian;
    • Kim, Jin Seok;
    • Kim, Kihyun;
    • King, Tracy
    Publication type:
    Article
    46

    Randomized, placebo-controlled, phase 3 study of perifosine combined with bortezomib and dexamethasone in patients with relapsed, refractory multiple myeloma previously treated with bortezomib.

    Published in:
    EJHaem, 2020, v. 1, n. 1, p. 1, doi. 10.1002/jha2.4
    By:
    • Richardson, Paul G.;
    • Nagler, Arnon;
    • Ben-Yehuda, Dina;
    • Badros, Ashraf;
    • Hari, Parameswaran N.;
    • Hajek, Roman;
    • Spicka, Ivan;
    • Kaya, Hakan;
    • LeBlanc, Richard;
    • Sung-Soo Yoon;
    • Kihyun Kim;
    • Martinez-Lopez, Joaquin;
    • Moshe Mittelman;
    • Shpilberg, Ofer;
    • Blake, Paul;
    • Teru Hideshima;
    • Colson, Kathleen;
    • Laubach, Jacob P.;
    • Ghobrial, Irene M.;
    • Leiba, Merav
    Publication type:
    Article
    47
    48
    49
    50